Sputnik Light: Single-dose will be enough against Corona, approved for trial in India

Posted on 15th Sep 2021 by rohit kumar

Russia's Sputnik Lite vaccine has been approved by the Drug Controller of India for Phase III trials in India. Emergency use of this vaccine will also be approved as soon as the trial is completed. After this, India will be able to get another weapon in the war against Corona.

 

 

Let us tell you that only a single dose of the Sputnik Light vaccine will be enough against the coronavirus. The vaccines currently being used in India are all double-dose vaccines.

 

 

The subject expert committee had recommended

The subject expert committee for Corona had recommended the third phase trial of Russia's Sputnik Light vaccine. Not only this, but the committee had also sent a recommendation for the approval of its emergency use, which was rejected saying that the vaccine has not yet been tried in India. The company says that the same components have been used in Sputnik Lite, which are in Sputnik-V. Therefore, the data on its impact on the Indian population is already ready.

 

Sputnik-V vs Sputnik Lite

Sputnik-V is a two-shot vaccine that uses two different vectors. According to a study published in the medical journal Lancet, its efficacy against corona is close to 91.6 percent. At the same time, Sputnik Lite is the first component of the Sputnik-V vaccine. According to data collected by the Ministry of Health of Buenos Aires Province (Argentina), the efficacy of this vaccine was found to be between 78.6 and 83.7 percent.

 

Why is Sputnik Light special?

There is a question in the minds of people that what might be the need for Sputnik Light after the already in use Sputnik-V vaccine? In this regard, health experts say that the primary advantage of the lite version of the vaccine is that this single-shot vaccine can play an important role in accelerating the pace of vaccination in a country amid rapid outbreaks of Covid-19. According to RDIF chief Kirill Dmitriev, Sputnik Light could prove to be a weapon to solve the challenge of immunizing large groups of people in a short time frame. With average effectiveness of 79.4 percent, this vaccine will be available at a very low price of 10 dollars per dose (about Rs 743).

Other news